Blisibimod ( DrugBank: Blisibimod )


5 diseases
IDDisease name (Link within this page)Number of trials
43Microscopic polyangiitis1
44Wegener granulomatosis1
49Systemic lupus erythematosus3
63Idiopathic thrombocytopenic purpura1
66IgA nephropathy8

43. Microscopic polyangiitis


Clinical trials : 88Drugs : 81 - (DrugBank : 21) / Drug target genes : 15 - Drug target pathways : 90 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

44. Wegener granulomatosis


Clinical trials : 98Drugs : 108 - (DrugBank : 28) / Drug target genes : 22 - Drug target pathways : 81 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 993Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 391Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 275Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries